Non-alcoholic Steatohepatitis Clinical Trial
Official title:
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients with biopsy-proven non-alcoholic steatohepatitis.
Type and design of the study: A randomized, placebo-controlled, double-blind, clinical trial to evaluate the efficacy of metadoxine as a therapy in patients with biopsy-proven nonalcoholic steatohepatitis. Population: Non-diabetic patients with nonalcoholic steatohepatitis diagnosed by liver biopsy through the "nonalcoholic fatty liver disease activity score" (NAS)> 3. Sample size: Considering a difference of at least 30% between groups, a confidence level of 95% (two-sided, significance 0.05), a statistical power of 80%, and an additional 20% for possible losses, we need 54 patients per group. Variables: Independent: Treatment group (metadoxine / placebo). Dependents: - "Nonalcoholic fatty liver disease activity score" (NAS):0 a 8 - Degree of liver steatosis: 0 a 3 - Degree of lobular inflammation: 0 a 3 - Degree of ballooning: 0 a 2 - Degree of fibrosis: 0 a 2 - Weight: Kg - Body mass index: Kg/m2 - Waist circumference: cm - Serum alanine aminotransferase: U/L - Serum aspartate aminotransferase: U/L Methods: Those meeting the selection criteria will be invited to participate in this study, those who agree to participate must sign the consent form and will be randomized to placebo or metadoxine group. The duration of the therapy will be 6 months and after this period a second liver biopsy will be performed to assessed the improvement on liver histology. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05945537 -
A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
|
Phase 1 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Recruiting |
NCT05065593 -
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
|
N/A | |
Terminated |
NCT04171765 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Active, not recruiting |
NCT02912260 -
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT06054815 -
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
|
Phase 2 | |
Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
Not yet recruiting |
NCT06160271 -
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
|
Phase 2 | |
Active, not recruiting |
NCT05573204 -
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis
|
Phase 2 | |
Completed |
NCT04042142 -
Glucagon Resistance in Patients With NAFLD
|
N/A | |
Completed |
NCT04657523 -
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
|
N/A | |
Completed |
NCT04142424 -
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
|
Phase 1 | |
Terminated |
NCT02787304 -
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
Completed |
NCT02528305 -
The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
|
N/A | |
Recruiting |
NCT01056133 -
Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT02960204 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
Completed |
NCT04806750 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
Recruiting |
NCT05751720 -
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
|
Phase 1/Phase 2 |